CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：AIM™ platform: A new immunotherapy approach for viral diseases.
AIM™ platform: A new immunotherapy approach for viral diseases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
除急性疾病的并发症外，慢性病毒感染还与恶性肿瘤和自身免疫性疾病相关。针对Epstein-Barr病毒（EBV）、人类T淋巴细胞病毒1型（HTLV-1）和人乳头瘤病毒（HPV）的充分治疗方案仍然缺乏。NexImmune人工免疫调节（AIM）纳米颗粒平台可通过模拟树突状细胞功能来引导T细胞应答。在一项应用中，AIM纳米颗粒在体外用于富集和扩增（E+E）罕见的多抗原特异性CD8+ T细胞群体，以将这些细胞用作AIM过继性细胞治疗。
本研究已证明，使用E+E CD8+ T细胞靶向EBV、HTLV-1和HPV的功能相关性。扩增后的T细胞主要包括效应记忆T细胞、中枢记忆T细胞和自我更新的干细胞样记忆T细胞，这些细胞靶向由AIM纳米颗粒呈递的选定病毒抗原肽。针对EBV或HPV抗原扩增的T细胞具有高度多能性，并对表达相应抗原的细胞系表现出显著的体外细胞毒性活性。
我们的初步工作是在探索从健康供者扩增且限制于人类白细胞抗原（HLA）-A*02:01血清型的T细胞的背景下进行的。AIM过继性细胞治疗（ACT）也正在针对其他HLA I类血清型进行开发。针对与急性髓系白血病和多发性骨髓瘤相关抗原的特异性自体或异体T细胞的AIM过继性细胞治疗目前正在临床中开展。AIM纳米颗粒平台的实用性和灵活性将随着我们推进第二个应用而扩展，即一种AIM可注射现成纳米颗粒，它靶向多种抗原特异性T细胞群体，以在体内直接激活、耐受或破坏这些靶向CD8+ T细胞，而不影响非靶细胞。AIM可注射平台为开发治疗感染性疾病、癌症和自身免疫性疾病的新型多抗原特异性疗法提供了潜力。
In addition to complications of acute diseases, chronic viral infections are linked to both malignancies and autoimmune disorders. Lack of adequate treatment options for Epstein-Barr virus (EBV), Human T-lymphotropic virus type 1 (HTLV-1), and human papillomavirus (HPV) remains.
The NexImmune Artificial Immune Modulation (AIM) nanoparticle platform can be used to direct T cell responses by mimicking the dendritic cell function. In one application, AIM nanoparticles are used ex vivo to enrich and expand (E+E) rare populations of multi-antigen-specific CD8 + T cells for use of these cells as an AIM adoptive cell therapy.
This study has demonstrated using E+E CD8 + T cells, the functional relevance of targeting EBV, HTLV-1, and HPV. Expanded T cells consist primarily of effector memory, central memory, and self-renewing stem-like memory T cells directed at selected viral antigen peptides presented by the AIM nanoparticle. T cells expanded against either EBV- or HPV-antigens were highly polyfunctional and displayed substantial in vitro cytotoxic activity against cell lines expressing the respective antigens.
Our initial work was in the context of exploring T cells expanded from healthy donors and restricted to human leukocyte antigen (HLA)-A*02:01 serotype. AIM Adoptive Cell Therapies (ACT) are also being developed for other HLA class I serotypes. AIM adoptive cell therapies of autologous or allogeneic T cells specific to antigens associated with acute myeloid leukemia and multiple myeloma are currently in the clinic.
The utility and flexibility of the AIM nanoparticle platform will be expanded as we advance the second application, an AIM injectable off-the-shelf nanoparticle, which targets multiple antigen-specific T cell populations to either activate, tolerize, or destroy these targeted CD8 + T cells directly in vivo, leaving non-target cells alone. The AIM injectable platform offers the potential to develop new multi-antigen specific therapies for treating infectious diseases, cancer, and autoimmune diseases.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
